Oak Thistle LLC Cuts Position in DexCom, Inc. (NASDAQ:DXCM)

Oak Thistle LLC reduced its holdings in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 84.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 6,223 shares of the medical device company's stock after selling 34,301 shares during the period. Oak Thistle LLC's holdings in DexCom were worth $484,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Geode Capital Management LLC lifted its position in shares of DexCom by 2.2% during the 3rd quarter. Geode Capital Management LLC now owns 9,937,604 shares of the medical device company's stock valued at $664,056,000 after buying an additional 214,136 shares in the last quarter. Jennison Associates LLC lifted its holdings in DexCom by 1,683.2% during the third quarter. Jennison Associates LLC now owns 6,932,899 shares of the medical device company's stock valued at $464,782,000 after purchasing an additional 6,544,102 shares in the last quarter. Legal & General Group Plc boosted its position in shares of DexCom by 1.7% in the second quarter. Legal & General Group Plc now owns 2,993,049 shares of the medical device company's stock worth $339,352,000 after purchasing an additional 49,076 shares during the period. Groupama Asset Managment increased its stake in shares of DexCom by 1.1% in the third quarter. Groupama Asset Managment now owns 2,851,556 shares of the medical device company's stock worth $1,912,000 after purchasing an additional 31,358 shares in the last quarter. Finally, Westfield Capital Management Co. LP raised its position in shares of DexCom by 44.6% during the 3rd quarter. Westfield Capital Management Co. LP now owns 2,842,057 shares of the medical device company's stock valued at $190,532,000 after purchasing an additional 876,739 shares during the period. 97.75% of the stock is currently owned by institutional investors.

DexCom Trading Down 0.5 %

Shares of DXCM traded down $0.46 during midday trading on Friday, hitting $84.38. The stock had a trading volume of 5,134,065 shares, compared to its average volume of 3,952,632. The stock's 50 day moving average is $77.89 and its 200 day moving average is $78.41. The firm has a market cap of $32.96 billion, a PE ratio of 50.53, a price-to-earnings-growth ratio of 2.00 and a beta of 1.12. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12. DexCom, Inc. has a 1 year low of $62.34 and a 1 year high of $142.00.

Insiders Place Their Bets

In other news, EVP Sadie Stern sold 4,259 shares of the firm's stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total transaction of $318,275.07. Following the transaction, the executive vice president now directly owns 71,192 shares of the company's stock, valued at approximately $5,320,178.16. This trade represents a 5.64 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 0.30% of the company's stock.

Analysts Set New Price Targets

Several brokerages recently weighed in on DXCM. Robert W. Baird raised shares of DexCom from a "neutral" rating to an "outperform" rating and upped their target price for the stock from $86.00 to $104.00 in a report on Thursday. Royal Bank of Canada cut their target price on DexCom from $120.00 to $115.00 and set an "outperform" rating for the company in a research report on Friday, October 25th. Baird R W raised DexCom from a "hold" rating to a "strong-buy" rating in a report on Thursday. Leerink Partners cut their price objective on shares of DexCom from $90.00 to $87.00 and set an "outperform" rating for the company in a report on Friday, October 25th. Finally, Canaccord Genuity Group lifted their price objective on shares of DexCom from $89.00 to $99.00 and gave the company a "buy" rating in a research report on Monday, December 9th. Five equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, DexCom presently has an average rating of "Moderate Buy" and an average price target of $99.29.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.